Press "Enter" to skip to content

New patent for Novo Nordisk drug XULTOPHY 100/3.6

0
Copyright © DrugPatentWatch. Originally published at New patent for Novo Nordisk drug XULTOPHY 100/3.6

Annual Drug Patent Expirations for XULTOPHY+100%2F3.6
Annual Drug Patent Expirations for XULTOPHY+100%2F3.6

Xultophy 100/3.6 is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from one supplier. There are seventeen patents protecting this drug.

Drug patent litigation for XULTOPHY 100/3.6.

This drug has two hundred and thirty-six patent family members in twenty-seven countries.

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. One supplier is listed for this compound. Additional details are available on the insulin degludec; liraglutide profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Copyright © DrugPatentWatch. Originally published at New patent for Novo Nordisk drug XULTOPHY 100/3.6
    Do NOT follow this link or you will be banned from the site!